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eply
irst, we express our deep appreciation for the sincere criticism by
r. Kaneda and colleagues of our paper (1). However, we have a
ew concerns regarding their arguments.
. The REVERSAL (REVERSing Atherosclerosis with Aggressive
Lipid Lowering) study (2) examined patients with stable coronary
artery disease who could undergo an elective cardiac catheteriza-
tion, whereas the PROVE-IT–TIMI 22 (Pravastatin or Atorva-
statin Evaluation and Infection Therapy–Thrombolysis In Myo-
cardial Infarction 22) (3) and our JAPAN-ACS (Japan
Assessment of Pitavastatin and Atorvastatin in Acute Coronary
Syndrome) study examined patients with acute coronary syn-
drome. Several reports have been published that nonculprit plaque
differs in tissue characteristics between acute coronary syndrome
and stable coronary artery disease. Therefore, extrapolations of the
data between the REVERSAL and the PROVE-IT–TIMI 22
studies have major limitations.
. Their criticism was not based on any kind of rational statistical
meta-analysis. The value of the difference in the mean percent-
age of change in plaque volume of 1.3% in the REVERSAL
study cannot necessarily be considered similar to the 1.1% in
our study. The value of 1.3% of the REVERSAL study came
from the difference between 5.4% and 4.1%, whereas the value
of 1.1% in our study resulted from the difference between
16.9% and 18.1%. Therefore, 1.3% of the REVERSAL
study might be considerably more remarkable than 1.1% in our
study.
. The intravenous ultrasound measurement of plaque volume
differed between the REVERSAL study and our study. The
REVERSAL study measured the longer segment with a total
of 30 mm or more integrated with 1-mm interval cross-
sectional area tracings, whereas our study measured a specific
plaque segment of a total length of approximately 7 mm with
0.1-mm interval tracings. Therefore, even a similar differ-
ence in the mean percentage of change in plaque volume in
the REVERSAL study might have a more significant clinical
impact on future cardiac events than that in our study.
akafumi Hiro, MD
akeshi Kimura, MD
akeshi Morimoto, MD
atsumi Miyauchi, MD
oshihisa Nakagawa, MD
asakazu Yamagishi, MD
ukio Ozaki, MD
azuo Kimura, MD
atoshi Saito, MD
etsu Yamaguchi, MD
iroyuki Daida, MDMasunori Matsuzaki, MD mDepartment of Medicine and Clinical Science
ivision of Cardiology
amaguchi University Graduate School of Medicine
-1-1 Minamikogushi
be, Yamaguchi 755-8505
apan
-mail: masunori@yamaguchi-u.ac.jp
doi:10.1016/j.jacc.2009.08.056
EFERENCES
. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on
regression of coronary atherosclerosis in patients with acute coronary
syndrome: a multicenter randomized trial evaluated by volumetric intravas-
cular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS
[Japan assessment of pitavastatin and atorvastatin in acute coronary syn-
drome] study). J Am Coll Cardiol 2009;54:293–302.
. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive
compared with moderate lipid-lowering therapy on progression of
coronary atherosclerosis: a randomized controlled trial. JAMA 2004;
291:1071–80.
. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus
moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med 2004;350:1495–504.
he BALANCE Study
oo Early to Speculate
n Mortality Effects
e read with great interest the paper by Yousef et al. (1) and the
ccompanying editorial (2) demonstrating and discussing long-
erm data on cardiac function and mortality in patients treated
ith autologous bone marrow cell (BMC) transplantation after
yocardial infarction.
We do not agree with the editorial’s statement that, based on
he new data, BMC infusion “can now be considered safe and
odestly efficacious” (2), despite the finding that fatal events were
ore frequent in the control group. The patient cohort studied and
he event rate observed were far too small to draw such conclu-
ions. The total number of fatal events was only 8. Also, if the
uthors had included hospitalizations in the analyses, as is often
one in outcome studies, such a combined end point would not
ave provided conclusive results. Of note, taking the results from
able 1 of their paper (1), there were 9 unplanned hospitalizations
n the BMC group and 8 in the intervention group.
In addition, a recent 4-year follow-up study with 86 patients,
espite slight improvements in cardiac function, could not identify
ignificant differences in myocardial viability or mortality (3). The
ALANCE (Clinical Benefit and Long-Term Outcome After In-
racoronary Autologous Bone Marrow Cell Transplantation in Pa-
ients With Acute Myocardial Infarction) trial thus may be viewed as
successful proof-of-principle study, but there still is a need for
arge-scale, placebo-controlled, double-blind clinical end point studies
o justify any conclusion with regard to safety or even mortality.
ortunately, such large trials are currently underway at several places
orldwide and will clarify those important outstanding issues.
Furthermore, the authors addressed paracrine effects of trans-
lanted autologous cells as the major mechanism explaining the
eneficial effects of BMC transplantation. In our view, additional
echanisms should be taken into account. BMC transplantation
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January 19, 2010:255–69nto an ischemic area results in modulation of the local tissue
mmune system and altered cytokine production (4). Indeed, BMC
ransplantation results in local inflammatory changes that activate
yofibroblasts, thus reducing infarct size (5). Thus, modulation of
ro- and anti-inflammatory intramyocardial cytokine levels by
ransplanted cells and their crosstalk with the local tissue environ-
ent likely affect survival and differentiation of progenitor cells, as
ell as overall cardiac outcome.
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eply
he letter by Drs. Thum and Anker touches various aspects of
ardiac stem cell therapy (e.g., mortality, paracrine effects, and
nflammation), all of which may be briefly addressed as follows.
Intracoronary stem cell therapy seems to represent a safe and
ffective regimen for treatment of heart failure after acute myocar-
ial infarction (1,2), in an old myocardial infarction (8 years)
ith ischemic cardiomyopathy (3), and in advanced dilated car-
iomyopathy (4). Our study (5) did not aim to speculate (Drs.
hum and Anker) on stem cell-induced inflammation (which has
ot yet been documented in the overwhelming majority of studies)
nd on possible paracrine effects by stem cells, but fortunately was
ble to analyze the different parameters of ventricular performance
nd potential effects on cardiac mortality in large patient groups,
reated and untreated, in long-term follow-up after myocardial
nfarction.
When carefully reading our paper (5), the BALANCE (Clinical
enefit and Long-Term Outcome After Intracoronary Autologous
one Marrow Cell Transplantation in Patients With Acute
yocardial Infarction) study showed that mortality, as a conse-
uence of stem cell therapy, is significantly reduced; in a median
ollow-up time of 4.6  2.1 years in the bone marrow cell group ppatient died, and in 4.8  2.2 years, 7 patients in the control
roup died (p  0.03).
Mortality is dependent on both the degree of ventricular
mpairment and the amount of arrhythmogenicity. Dependent on
he multifactorial mode of action of stem cells, systolic function
e.g., ejection fraction, stroke volume, contractility) and diastolic
erformance are improved; infarct size, end-systolic volume, and
ystolic wall stress decrease; and the arrhythmogenicity of the heart
s presumably reduced. Thus, several of the main myocardial
eterminants of cardiac mortality are influenced in favor of reduced
ortality by stem cell treatment in chronically ill cardiac patients.
Undoubtedly, further large studies are needed to analyze the
ction of stem cells on ventricular performance and cardiac
ortality in different stages of chronic cardiac failure, especially
ith regard to the distinct origin of this chronic disease.
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rade of Ischemia to Assess
o Reflow After Reperfusion
e read with great interest the excellent review by Niccoli et al. (1)
bout the no-reflow phenomenon in humans. In their paper, the
uthors describe various techniques for the prediction of no-reflow.
s far as electrocardiography is concerned, the authors only
ention the QRS score as a predictor of ischemia-related injury.
The extent of terminal QRS distortion on the admission
lectrocardiogram, known as the grade of ischemia, is a strong
redictor of failure of ST-segment resolution as well as of
